NCT04635111
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 12 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial status changed: Recruiting → Withdrawn Sponsor's reason: FDA release from PMR Show 5 more changesShow less
- Enrollment target: estimated 30 to confirmed 0
- Eligibility criteria expanded, about 9 words
- Primary completion date changed from estimate of Jun 1, 2036 to Jul 24, 2026
- Study sites: 8 to 6
- Secondary endpoints: details revised at 1 of 3 entries
- Minor Study description expanded, about 1 wordv18
- Notable Primary and study completion dates pushed to Jun 1, 2036v17
- Minor Study sites: 6 to 8
- Primary completion date: Jun 2025 to Jun 1, 2025
- Study completion date: Mar 2036 to Mar 1, 2036
- Minor Site details revised at 1 of 6 sitesv12
Show 6 earlier versionsHide 6 earlier versions
- Minor Study sites: 5 to 6v10
- Minor Site details revised at 1 of 5 sitesv9
- Minor Study sites: 2 to 5v5
- Minor Study sites: 1 to 2v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Dec 20, 2020 to Jan 7, 2021
- Notable Start date: Nov 20, 2020 to Dec 20, 2020v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Frequency of Hepatic Failure After Discontinuation of TURALIO™ (pexidartinib)
Timeframe: Baseline up to 10 years
Secondary (3)
Number of Participants With Liver Test Abnormalities
Number of Participants With A Liver Transplant
Number of Participants Experiencing Death
Arms and interventions
Symptomatic TGCT Participants
Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience moderate or severe hepatotoxicity due to use of TURALIO™ (pexidartinib).
Drugs: TURALIO™
Sites
6 sites in 1 country